Noble Capital analyst Patrick McCann lowered the firm’s price target on GoHealth (GOCO) to $20 from $25 and keeps an Outperform rating on the shares after the company reported Q2 revenue below the firm’s forecast. The firm now expects Q3 revenue to moderate to $100M, down from its prior estimate, and it trimmed both revenue and adjusted EBITDA estimates for 2025, but it continues to anticipate revenue growth and margin expansion in 2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GOCO: